Psychedelic medicines are moving from clinical promise toward real-world use, and the questions facing companies in this space are shifting accordingly. Positive late-stage data, a more supportive regulatory climate, and a wave of Big Pharma investment have changed the conversation from whether these therapies work to what it will take for them to succeed. In this white paper, Blue Matter’s Jordan Burgess examines five issues that will shape the field
- Overcoming stigma while managing hype
- Navigating an evolving regulatory landscape
- Designing care-delivery models that scale
- Answering the retreatment and reimbursement question
- Meeting a higher bar for strategic value.
For each, she outlines what companies need to figure out now to build therapies that patients can access, providers can deliver, and payers can support. In addition, she addresses the critical need for primary research and deep insights to guide decision makers through each issue. Download the full paper to explore the decisions that will define the path from promise to practice.
